Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1402 postoperative IMRT-CCRT for high-risk cervical cancer
jRCTs031180194Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin in Cervical Cancer (CC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year relapse-free survival. Started Jun 2017; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCTs031180194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180194.